Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: pulmonary fibrosis + idiopathic fibrosis + fibrosis  Related to the article below (Last Update: 8/5/2008)

Pulmonary Fibrosis Research Enhancement Act of 2008 Introduced in ...
MarketWatch - Jul 23, 2008
Not much is known about Pulmonary Fibrosis (PF), a progressive and ultimately fatal lung disease that claims the lives of 40000 Americans each year and ...
Note To People With Scarred And Stiffened Lungs: Monitor Your ...
Medical News Today (press release), UK - Jul 31, 2008
But Spaeth was also diagnosed with pulmonary fibrosis, a hard-to-treat disease that progressively damages the lungs and starves the body of oxygen. ...
Cystic Fibrosis: Newborn Screening in America
RedOrbit, TX - Jul 31, 2008
These derangements prompt liver stellate cells to synthesize collagen, leading to fibrosis." Liver disease is the most common non- pulmonary cause of death ...
Medical Edge: Treating pulmonary fibrosis can be a challenge
Post-Bulletin, MN - Jul 7, 2008
Even though idiopathic pulmonary fibrosis has no known cure in 2008, more clinical research studies and new medications have been advanced for the treatment ...
InterMune Reports Second Quarter 2008 Financial Results and ...
CNNMoney.com (press release) - Jul 31, 2008
InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes ...ITMN
InterMune Reports Second Quarter 2008 Financial Results and ...
PharmaLive.com (press release), PA - Aug 1, 2008
... results from our Phase 3 CAPACITY program for pirfenidone in idiopathic pulmonary fibrosis, a fatal disease for which no treatments are approved. ...ITMN
Indianapolis Company Recognized as Leading Biotechnology Innovator
Inside INdiana Business (press release), IN - Jul 8, 2008
Most importantly, we are working aggressively to translate the science Idiopathic Pulmonary Fibrosis,? stated David S. Wilkes, MD ImmuneWorks founder and ...
Robert L. Mather
The Oregonian - OregonLive.com, OR - Jul 14, 2008
... July 16, 2008, in Foothills Community Church in Molalla for Robert L. Mather, who died July 11 of idiopathic pulmonary fibrosis at age 48. ...
InterMune to Present at BMO Healthcare Conference
Earthtimes (press release), UK - Jul 30, 2008
InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. ...ITMN
InterMune to Present at BMO Healthcare Conference
Trading Markets (press release), CA - Jul 30, 2008
InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. ...ITMN - OTC:CMTX
Source: Google News

Idiopathic Pulmonary Fibrosis Clinical Relevance of Pathologic Classification -
ALA KATZENSTEIN, JL MYERS - American Journal of Respiratory and Critical Care Medicine, 1998 - Am Thoracic Soc
... Idiopathic Pulmonary Fibrosis Clinical Relevance of Pathologic Classification. ...
PATHOLOGIC CLASSIFICATION OF IDIOPATHIC PULMONARY FIBROSIS. ...

… with Interferon Gamma-1b and Low-Dose Prednisolone in Patients with Idiopathic Pulmonary Fibrosis -
R Ziesche, E Hofbauer, K Wittmann, V Petkov, LH … - New England Journal of Medicine, 1999 - content.nejm.org
... Next Next. A Preliminary Study of Long-Term Treatment with Interferon Gamma-1b and
Low-Dose Prednisolone in Patients with Idiopathic Pulmonary Fibrosis. ...

Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis -
JA BJORAKER, JAYH RYU, MK EDWIN, JL MYERS, HD … - American Journal of Respiratory and Critical Care Medicine, 1998 - Am Thoracic Soc
... Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis. ...
Idiopathic pulmonary fibrosis: a rational clinical approach. ...

Idiopathic Pulmonary Fibrosis -
TJ Gross, GW Hunninghake - New England Journal of Medicine, 2001 - content.nejm.org
Idiopathic Pulmonary Fibrosis. Thomas J. Gross, MD, and Gary W. Hunninghake, MD. ...
Review: New perspectives in the treatment of idiopathic pulmonary fibrosis. ...

Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and … -
M Selman, TE King Jr, A Pardo - Annals of Internal Medicine, 2001 - annals.highwire.org
... Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its
Pathogenesis and Implications for Therapy. ... Familial idiopathic pulmonary fibrosis. ...

A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis -
G Raghu, KK Brown, WZ Bradford, K Starko, PW Noble … - New England Journal of Medicine, 2004 - content.nejm.org
... Next Next. A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with
Idiopathic Pulmonary Fibrosis. ... Acute Exacerbation of Idiopathic Pulmonary Fibrosis. ...

Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, …
RG Crystal, JD Fulmer, WC Roberts, ML Moss, BR … - Ann Intern Med, 1976 - ncbi.nlm.nih.gov
Idiopathic pulmonary fibrosis. ... Idiopathic pulmonary fibrosis is a fatal disorder
that starts as an alveolitis and progresses to interstitial fibrosis. ...

… immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis … -
N Khalil, RN O'Connor, HW Unruh, PW Warren, KC … - Am J Respir Cell Mol Biol, 1991 - ncbi.nlm.nih.gov
1991 Aug;5(2):155-62. Increased production and immunohistochemical localization
of transforming growth factor-beta in idiopathic pulmonary fibrosis. ...

Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary … -
S Nagai, M Kitaichi, H Itoh, K Nishimura, T Izumi, … - European Respiratory Journal, 1998 - Eur Respiratory Soc
... Original Articles. Idiopathic nonspecific interstitial pneumonia/fibrosis:
comparison with idiopathic pulmonary fibrosis and BOOP. ...

… beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. -
TJ Broekelmann, AH Limper, TV Colby, JA McDonald - Proceedings of the National Academy of Sciences of the …, 1991 - pubmedcentral.nih.gov
... Abstract. Idiopathic pulmonary fibrosis is an inexorably fatal disorder characterized
by connective tissue deposition within the terminal air spaces resulting ...

Source: Google Scholar

Translational research patented first experimental treatment against idiopathic pulmonary fibrosis

Innovative pneumocytes transplantation has reverted the disease for the first time in rats

 

Idiopathic pulmonary fibrosis is a disease with unknown cause with a very severe prognosis; when detected, it is already in an advanced stage. Patients suffering from it cannot develop with normality pulmonary gas exchange, and have a very reduced quality of life. Because of lack of an effective treatment, they rarely survive 5 years after being diagnosed. Idiopathic pulmonary fibrosis affects 13 out of 100,000 men and 7 out of 100,000 women, normally over 40 years of age. Researchers from the Biomedical Research Institute of Barcelona CSIC (IIBB-CSIC), a centre developing research in the framework of the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), have discovered and patented a method to stop and revert this disease in an animal model. A clinical study will be soon conducted in humans in the Hospital Clínic de Barcelona.

Results of their research work are published in the last issue of the American Journal of Respiratory and Critical Care Medicine (176(12):1261-8). This study has had the collaboration of basic researchers, such as Dr. Anna Serrano-Mollar, and Dr. Oriol Bulbena, first and last signatories of the study; and researchers with a clinical background, such as Dr. Antoni Xaubet, from the Unit of Pneumology of the Hospital Clínic de Barcelona. This turns this work into a paradigm of translational research promoted in IDIBAPS and through other initiatives such as the Network of Centres of Biomedical Research (CIBERs). This research work has been financed through a contribution from the Fondo de Investigaciones Sanitarias (FIS) from the Instituto de Salud Carlos III.

Gas exchange is developed in lungs thanks to type 1 pneumocytes in alveoli, cells recovering the inner walls of the alveolar cavity. Occupying the same spaces, there are also type II pneumocytes, precursor cells that repair the damaged alveolar tissue. When idiopathic pulmonary fibrosis appears, this regeneration process cannot be developed correctly and fibrosis advances until respiration is impossible. The technique developed by researchers from the IIBB-CSIC-IDIBAPS consists in a transplantation of type II pneumocytes via intratracheal. In order to monitor correctly the transplanted cells with genetic and fluorescence techniques, sexual chromosomal differences were used. Thus, the disease was induced in female rats, and cells from male rats were transplanted. This is a lowly invasive technique which has permitted to regenerate, for the first time, rat fibrotic alveoli where idiopathic pulmonary fibrosis was induced.

CSIC has patented as a treatment the cell suspension transplanted with this innovative strategy. The world patent will be proved in humans with a clinical study, soon conducted in the Hospital Clínic de Barcelona thanks to the financing of the Fundación Genoma España and CSIC This study will have the participation of 6 recently diagnosed patients who will receive a suspension of type II pneumocytes coming from a dead donor, since these cells cannot be cultured in the laboratory. All this events throw new and hopeful light into basic and clinical research lines. One of the following steps of researchers will be to try to obtain type II pneumocytes from adult stem cells.

###

Further information:

Communication Area IDIBAPS
Marc de Semir, Head of Communication (mdesemir@clinic.ub.es)
Àlex Argemí, scientific editor (aargemi@clinic.ub.es)
Tel.: 00 34 93 227 57 00

 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
ALL THE NEWS : News1 ; News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.